268 related articles for article (PubMed ID: 23257685)
1. Sputum hyaluronan and versican in severe eosinophilic asthma.
Ayars AG; Altman LC; Potter-Perigo S; Radford K; Wight TN; Nair P
Int Arch Allergy Immunol; 2013; 161(1):65-73. PubMed ID: 23257685
[TBL] [Abstract][Full Text] [Related]
2. Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.
Mukherjee M; Aleman Paramo F; Kjarsgaard M; Salter B; Nair G; LaVigne N; Radford K; Sehmi R; Nair P
Am J Respir Crit Care Med; 2018 Jan; 197(1):38-46. PubMed ID: 28915080
[TBL] [Abstract][Full Text] [Related]
3. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma.
Sehmi R; Smith SG; Kjarsgaard M; Radford K; Boulet LP; Lemiere C; Prazma CM; Ortega H; Martin JG; Nair P
Clin Exp Allergy; 2016 Jun; 46(6):793-802. PubMed ID: 26685004
[TBL] [Abstract][Full Text] [Related]
4. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.
McDowell PJ; Diver S; Yang F; Borg C; Busby J; Brown V; Shrimanker R; Cox C; Brightling CE; Chaudhuri R; Pavord ID; Heaney LG;
Lancet Respir Med; 2021 Oct; 9(10):1174-1184. PubMed ID: 33971168
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials.
Liu Y; Zhang S; Li DW; Jiang SJ
PLoS One; 2013; 8(3):e59872. PubMed ID: 23544105
[TBL] [Abstract][Full Text] [Related]
6. Anti-IL-5 in Mild Asthma Alters Rhinovirus-induced Macrophage, B-Cell, and Neutrophil Responses (MATERIAL). A Placebo-controlled, Double-Blind Study.
Sabogal Piñeros YS; Bal SM; van de Pol MA; Dierdorp BS; Dekker T; Dijkhuis A; Brinkman P; van der Sluijs KF; Zwinderman AH; Majoor CJ; Bonta PI; Ravanetti L; Sterk PJ; Lutter R
Am J Respir Crit Care Med; 2019 Feb; 199(4):508-517. PubMed ID: 30192638
[TBL] [Abstract][Full Text] [Related]
7. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.
Nair P; Pizzichini MM; Kjarsgaard M; Inman MD; Efthimiadis A; Pizzichini E; Hargreave FE; O'Byrne PM
N Engl J Med; 2009 Mar; 360(10):985-93. PubMed ID: 19264687
[TBL] [Abstract][Full Text] [Related]
8. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.
Flood-Page P; Swenson C; Faiferman I; Matthews J; Williams M; Brannick L; Robinson D; Wenzel S; Busse W; Hansel TT; Barnes NC;
Am J Respir Crit Care Med; 2007 Dec; 176(11):1062-71. PubMed ID: 17872493
[TBL] [Abstract][Full Text] [Related]
9. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study.
Castro M; Mathur S; Hargreave F; Boulet LP; Xie F; Young J; Wilkins HJ; Henkel T; Nair P;
Am J Respir Crit Care Med; 2011 Nov; 184(10):1125-32. PubMed ID: 21852542
[TBL] [Abstract][Full Text] [Related]
10. Mepolizumab treatment in patients with severe eosinophilic asthma.
Ortega HG; Liu MC; Pavord ID; Brusselle GG; FitzGerald JM; Chetta A; Humbert M; Katz LE; Keene ON; Yancey SW; Chanez P;
N Engl J Med; 2014 Sep; 371(13):1198-207. PubMed ID: 25199059
[TBL] [Abstract][Full Text] [Related]
11. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
Liu MC; Chipps B; Munoz X; Devouassoux G; Bergna M; Smith SG; Price RG; Galkin DV; Azmi J; Mouneimne D; Albers FC; Chapman KR
Respir Res; 2021 May; 22(1):144. PubMed ID: 33971856
[TBL] [Abstract][Full Text] [Related]
12. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
[TBL] [Abstract][Full Text] [Related]
13. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
[TBL] [Abstract][Full Text] [Related]
14. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment.
Magnan A; Bourdin A; Prazma CM; Albers FC; Price RG; Yancey SW; Ortega H
Allergy; 2016 Sep; 71(9):1335-44. PubMed ID: 27087007
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Potential Continuation Rules for Mepolizumab Treatment of Severe Eosinophilic Asthma.
Gunsoy NB; Cockle SM; Yancey SW; Keene ON; Bradford ES; Albers FC; Pavord ID
J Allergy Clin Immunol Pract; 2018; 6(3):874-882.e4. PubMed ID: 29258789
[TBL] [Abstract][Full Text] [Related]
16. Mepolizumab in the treatment of severe eosinophilic asthma: Results from a physician in the field.
Strauss RA; Jawhari N
Ann Allergy Asthma Immunol; 2018 Jul; 121(1):121-123. PubMed ID: 29684570
[No Abstract] [Full Text] [Related]
17. Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety.
van Toor JJ; van der Mark SC; Kappen JH; In 't Veen JCCM; Braunstahl GJ
J Asthma; 2021 May; 58(5):651-658. PubMed ID: 31999203
[No Abstract] [Full Text] [Related]
18. Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response.
Caminati M; Cegolon L; Vianello A; Chieco Bianchi F; Festi G; Marchi MR; Micheletto C; Mazza F; Tognella S; Senna G
Expert Rev Respir Med; 2019 Dec; 13(12):1205-1212. PubMed ID: 31592700
[No Abstract] [Full Text] [Related]
19. Vitamin D reduces eosinophilic airway inflammation in nonatopic asthma.
de Groot JC; van Roon EN; Storm H; Veeger NJ; Zwinderman AH; Hiemstra PS; Bel EH; ten Brinke A
J Allergy Clin Immunol; 2015 Mar; 135(3):670-5.e3. PubMed ID: 25617224
[TBL] [Abstract][Full Text] [Related]
20. Mepolizumab and exacerbations of refractory eosinophilic asthma.
Haldar P; Brightling CE; Hargadon B; Gupta S; Monteiro W; Sousa A; Marshall RP; Bradding P; Green RH; Wardlaw AJ; Pavord ID
N Engl J Med; 2009 Mar; 360(10):973-84. PubMed ID: 19264686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
